Teijin Pharma Limited Reports Findings in Gout (Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan)

2021 JUL 05 (NewsRx) -- By a News Reporter-Staff News Editor at Daily Asia Business -- New research on Musculoskeletal Diseases and Conditions - Gout is the subject of a report. According to news reporting from Tokyo, Japan, by NewsRx journalists, research stated, “In patients with gout, treating to target serum uric acid levels (sUA) of 6.0 mg/dL is universally recommended to prevent gout flare. However, there is no consensus on asymptomatic hyperuricaemia.”

Financial support for this research came from Teijin Pharma Limited.

The news correspondents obtained a quote from the research from Teijin Pharma Limited, “Using Japanese health insurance claims data, we explored potential benefits of sUA control for preventing gout flare in subjects with asymptomatic hyperuricaemia. This retrospective cohort study analysed the JMDC Claims Database from April 2012 through June 2019. Subjects with sUA 8.0 mg/dL were identified, and disease status (prescriptions for urate-lowering therapy (ULT), occurrence of gout flare, sUA) was investigated for 1 year. Time to first onset and incidence rate of gout flare were determined by disease status subgroups for 2 years or more. The relationship between gout flare and sUA control was assessed using multivariable analysis. The analysis population was 19 261 subjects who met eligibility criteria. We found fewer occurrences of gout flare, for both gout and asymptomatic hyperuricaemia, in patients who achieved sUA 6.0 mg/dL with ULT than in patients whose sUA remained >6.0 mg/dL or who were not receiving ULT. In particular, analysis by a Cox proportional-hazard model for time to first gout flare indicated that the HR was lowest, at 0.45 (95% CI 0.27 to 0.76), in subjects with asymptomatic hyperuricaemia on ULT (5.0

According to the news reporters, the research concluded: “Occurrences of gout flare were reduced by controlling sUA at 6.0 mg/dL in subjects with asymptomatic hyperuricaemia as well as in those with gout.”

This research has been peer-reviewed.

For more information on this research see: Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan. Annals of the Rheumatic Diseases, 2021. Annals of the Rheumatic Diseases can be contacted at: Bmj Publishing Group, British Med Assoc House, Tavistock Square, London WC1H 9JR, England. (BMJ Publishing Group - http://group.bmj.com/; Annals of the Rheumatic Diseases - http://ard.bmj.com/)

Our news journalists report that additional information may be obtained by contacting Ruriko Koto, Medical Science Division, Teijin Pharma Ltd., Chiyoda-ku, Tokyo, Japan. Additional authors for this research include Akihiro Nakajima, Hideki Horiuchi and Hisashi Yamanaka.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1136/annrheumdis-2021-220439. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Annals of the Rheumatic Diseases is: Bmj Publishing Group, British Med Assoc House, Tavistock Square, London WC1H 9JR, England.

(Our reports deliver fact-based news of research and discoveries from around the world.)